• BCN PEPTIDES, a partner of the European Consortium for the use of SOLNATIDE in COVID-19 patients

    April 1, 2020


    The product Solnatide, developed by the Austrian company Apeptico Forschung und Entwicklung GmbH, is an investigational medicinal product for the treatment of various forms of life-threatening acute pulmonary dysfunction and pulmonary oedema in acute respiratory distress syndrome (ARDS) patients.

    Now, thanks to this Grant Agreement with the European Comission, Solnatide will be available for medical treatment of patients severely affected by the novel coronavirus 2019 (SARS-CoV-2) disease, COVID-19.

    In this emergency situation in hospitals across Europe, BCN PEPTIDES will manufacture Solnatide Active Pharmaceutical Ingredient for the therapeutic treatment of patients suffering from severe symptoms of infection with the SARS-CoV-2 novel coronavirus.